About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More


Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy

Study identifier: NCT00892736
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)


  • Documented BRCA1/2 mutation AND a BRCA-related malignancy (e.g., primarily
    breast or ovarian cancer, but may include prostate or pancreatic cancer) or triple-
    negative breast cancer. Progressive disease after standard therapy OR no acceptable standard treatment options available.
  • Platinum-refractory ovarian, fallopian tube, or primary peritoneal cancer
  • Patients with platinum-sensitive disease must have known BRCA mutations
  • Basal-like breast cancer, defined as estrogen and progesterone receptor-negative, HER2-negative, and/or expression profile of EGFR and cytokeratins 5/6 consistent with basal phenotype
    "Triple-negative" phenotype (i.e., negative hormone and HER2 receptors) allowed

Type of study:

Phase I


  • Patients receive oral ABT-888 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or toxicity.

Study sites:

City of Hope
Contact: Robert J. Morgan 626-256-4673 rmorgan@coh.org

Los Angeles
University of Southern California
Contact: Agustin A. Garcia 323-865-0832 aagarcia@usc.edu

UC Davis Comprehensive Cancer Center
Contact: David R. Gandara 916-734-3772 david.gandara@ucdmc.ucdavis.edu

South Pasadena
City of Hope - South Pasadena
Contact: Stephen C. Koehler 626-396-2900 Skoehler@cohmg.com

New Jersey
New Brunswick
Cancer Institute of New Jersey
Contact: Antoinette R. Tan 732-235-6777 tanan@umdnj.edu

Penn State Milton S Hershey Medical CenterPennsylvania
Contact: Chandra P. Belani 717-531-1078 cbelani@psu.edu

UPMC Cancer Center
Contact: Clinical Trials Office - UPMC Cancer Centers     412-647-8073  


Page updated 06/09/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us


This site has been made possible by a generous grant from Morphotek.

Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org